Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 [obesity therapies] in Overweight/Obese Male Subjects.

Trial Profile

Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 [obesity therapies] in Overweight/Obese Male Subjects.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NNC 0070-0002-0349 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2008 Planned end date changed from 1 Nov 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Aug 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top